Mode
Text Size
Log in / Sign up

Optical genome mapping identifies mosaic structural variants in surgically resected epilepsy brain tissueNew mapping tool finds hidden genetic changes in epilepsy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that OGM may identify mosaic structural variants in brain tissue that are missed by short read exome sequencing.

This case series examines the application of optical genome mapping (OGM) to surgically resected brain tissue in 4 patients with epilepsy and cortical malformations. The analysis focused on the ability of OGM to detect somatic structural variants and identify mechanisms for somatic deletions compared to short read exome sequencing.

The findings indicate that the OGM protocol yields ~450x effective coverage. The technology identified large and complex mosaic structural variants with a variant allele fraction ranging from 7 to 40%, most of which were not captured by short read exome sequencing. In one patient with a known germline DEPDC5 variant, OGM revealed a somatic 13.2kb deletion in DEPDC5 at approximately 20% VAF, which was mediated by the recombination of two flanking Alu elements.

A primary limitation noted is that OGM requires high quality, high molecular weight DNA from clinical specimens. While OGM appears to be a robust tool for detecting somatic structural variation in human brain tissue, its ability to improve diagnostic yield and refine genotype-phenotype correlations in neurological disorders warrants further investigation.

When doctors perform brain surgery to treat epilepsy, they sometimes find structural changes in the brain's development. For a long time, standard genetic tests have struggled to see the full picture of these mutations. Now, a new method called Optical Genome Mapping (OGM) is showing promise in finding much more detail.

In a small study of four patients, researchers used OGM to look at surgically removed brain tissue. They found that this tool can spot large and complex mutations—specifically mosaic structural variants—that traditional sequencing missed. These are mutations that only exist in a subset of cells, making them incredibly hard to track down.

In one specific case, the tool even pinpointed a hidden deletion in a gene called DEPDC5. The researchers discovered that this deletion happened because two pieces of DNA, known as Alu elements, essentially swapped places. This level of detail helps explain exactly how these genetic errors occur.

While these results are exciting, the technology is still in its early stages. To work well, OGM needs very high-quality DNA from clinical samples. It is currently being used as a powerful extra tool to help doctors better understand the genetic roots of neurological disorders.

What this means for you:
Optical Genome Mapping detects complex genetic mutations in brain tissue that standard sequencing often misses.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Somatic variants are a prominent cause of epilepsy associated cortical malformations, but about half of patients undergoing genetic testing have no finding due partly to limitations in variant detection. Most studies have focused on single nucleotide variants or small indels that are accessible to short read sequencing technologies, but somatic structural variants are also emerging as important contributors despite their unique detection challenges. Optical genome mapping (OGM) is a promising methodology for the detection of structural variants, but requires high quality, high molecular weight DNA from clinical specimens. Here we successfully optimize a protocol for OGM of surgically-resected patient brain tissue which yields ~450x effective coverage, suitable for detecting somatic variants at low allele fractions. We apply this approach to brain specimens from four patients with epilepsy. OGM identifies large and complex mosaic structural variants ranging from 7 to 40% variant allele fraction, most of which are not captured by short read exome sequencing of the same specimen. In one patient with a known germline DEPDC5 variant, OGM reveals a somatic variant, a 13.2kb deletion in DEPDC5 at approximately 20% VAF, consistent with the established two hit model in DEPDC5 associated lesional epilepsies. By resolving the breakpoints in PacBio HiFi sequencing data, we identify a mechanism for this somatic deletion, mediated by recombination of two Alu elements flanking the region. Our findings demonstrate that OGM is a robust and complementary tool for detecting somatic structural variation in human brain tissue, with potential to improve diagnostic yield and refine genotype phenotype correlations in neurological disorders.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.